Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Medicine


  • WASHINGTON— Lyme disease conjures memories of checking for ticks at camp and fretting over bug bites after hikes in the woods. But far from a summertime nuisance, Lyme is a potentially debilitating disease- and the subject of a vigorous debate in modern medicine. Lyme disease is caused by a strain of bacteria carried by certain ticks, primarily found in Northeast...

  • FDA approves OxyContin for children 11 and older Friday, 14 Aug 2015 | 7:51 AM ET

    The agency approved the powerful painkiller OxyContin for a new use in children 11 to 16 who are suffering from severe, long-term pain.

  • *Results of SUMMIT trial with Breo due as early as Sept. *U.S. partner Theravance eligible for royalties on sales. LONDON, Aug 13- GlaxoSmithKline is banking on a major clinical trial to revive its flagging respiratory medicine business, with billions of dollars of sales riding on a positive result.

  • Breast health stock on a tear Thursday, 13 Aug 2015 | 8:20 AM ET
    Breast health stock on a tear

    Medical diagnostics company Hologic CFO Robert McMahon, discusses growth opportunities underway, including in its mammogram technology.

  • Aug 12- AbbVie Inc on Wednesday said its experimental treatment for a form of leukemia associated with a gene mutation met its primary goal in a mid-stage trial and that the company would seek U.S. approval of the medicine, which analysts have said has blockbuster sales potential. AbbVie, which is developing the drug venetoclax with Switzerland's Roche Holding...

  • Aug 11- Drugmaker GlaxoSmithKline closed its North Carolina factory on Tuesday after testing at a cooling tower found bacteria that causes deadly Legionnaire's disease, a company spokeswoman said. The Legionella bacteria was discovered during routine inspections at the site in Zebulon, N.C., GSK spokeswoman Jenni Brewer Ligday said. City and state...

  • Can small & rural hospitals keep up? Tuesday, 11 Aug 2015 | 7:11 AM ET
    Can small & rural hospitals keep up?

    Insight to the future of the small community hospital, in the wake of mounting codes and regulations, with Tenet Healthcare President & CEO Trevor Fetter.

  • Aug 10- A vaccine developed by Novavax Inc was shown to prevent a common respiratory viral infection in a mid-stage study, taking it one step closer to becoming the first vaccine for the virus that affects almost all American children. Novavax's vaccine was similar to or better than a number of respiratory vaccines tested in the elderly, data presented on Monday...

  • Pfizer Inc, which is lagging rivals in the lucrative field of cancer immunotherapies, has been the first to report early data of an "accelerator" treatment that targets a protein called 4-1 BB. Bristol-Myers Squibb Co is hot on Pfizer's heels with a handful of early-stage trials of its own 4-1 BB antibody. Holbrook Kohrt, a researcher from Stanford University...

  • Spare Times for Aug. 7-13 Thursday, 6 Aug 2015 | 7:12 PM ET

    American Museum of Natural History:‘ Countdown to Zero’ Smallpox is the only human disease to have been eradicated, but what about Guinea worm, polio, malaria and others? Brooklyn Historical Society:‘ Mapping Brooklyn’ This exhibition, presented with BRIC House, features artworks that incorporate themes of mapping and cartography from historical maps.

  • Staying safe from peanut allergies Thursday, 6 Aug 2015 | 2:50 PM ET
    Staying safe from peanut allergies

    Stephen Dilly, Aimmune CEO, explains how his biotech company's peanut allergy treatments can help keep people safe from accidental exposure to the peanut protein.

  • A start-up founder hugging out health care Wednesday, 5 Aug 2015 | 10:28 AM ET
    A start-up founder hugging out health care

    Watch the founder of Sproutel pitch his start-up to a panel of experts on CNBC.

  • *Worldwide cancer drug spending $100 billion in 2014. LONDON, Aug 3- New cancer drug cocktails set to reach the market in the next few years will test the limits of premium pricing for life-saving medicines, forcing company executives to consider fresh market strategies. Pricey immunotherapies, offering long-lasting responses, are already starting to change...

  • There's more to Merck's Ebola vaccine than money Friday, 31 Jul 2015 | 2:18 PM ET
    A file photo of an Ebola vaccine trial in Liberia last February.

    A vaccine being developed by Merck and NewLink was shown to be 100 percent effective, but does this mean they'll make big bucks?

  • LONDON, July 31- Scientists and drug companies will continue to research the potential of alternative Ebola vaccines, despite a shot from Merck and NewLink Genetics proving 100 percent effective in a trial in Guinea. In the event, it proved about as safe as a flu vaccine, said University of Reading virologist Ben Neuman, but it was still not given to children or...

  • July 30- Amgen Inc on Thursday reported higher-than-expected second-quarter profit and revenue, helped by strong sales of its Enbrel rheumatoid arthritis drug and cost cutting, and the company raised its full-year forecasts. Excluding special items, Amgen earned $2.57 per share, topping analysts' average expectations by 14 cents, according to Thomson...

  • UPDATE 1-Sanofi's diabetes sales slow, Genzyme's jump Thursday, 30 Jul 2015 | 4:54 AM ET

    PARIS, July 30- Sanofi reported lower second quarter sales for its strategic diabetes division on Thursday, hurt by continued pricing pressure in the United States, but it's biotech arm Genzyme recorded another quarter of double-digit growth, enabling the French drugmaker to beat forecasts overall. Forced to agree to increased rebates to maintain market...

  • *HIV sales help offset margin slide post Novartis deal. LONDON, July 29- GlaxoSmithKline moved to reclaim its prowess as a research powerhouse on Wednesday by flagging up dozens of new drugs and vaccines in development, as demand for new HIV medicines helped it beat quarterly profit forecasts. The drugmaker recently sold its marketed cancer drugs to Novartis...

  • July 28- Gilead Sciences Inc said on Tuesday sales of its hepatitis C drugs hit a record of nearly $5 billion, surpassing Wall Street estimates as strong demand offset pricing pressures and restrictions on patient use from U.S. health insurers. Excluding items, Gilead earned $3.15 a share in the second quarter, beating the $2.71 average forecast by Wall Street...

  • Gilead posts huge beat on earnings and revenue Tuesday, 28 Jul 2015 | 5:28 PM ET
    A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, California.

    Gilead blew past top and bottom line expectations on the strength of strong sales for its hepatitis C treatments.